Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis (HERO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00234897|
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : August 29, 2007
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Drug: adalimumab||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1938 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)|
|Study Start Date :||August 2004|
- Patient reported outcomes, clinical response indicators.
- Subject reported assessments of disease activity, physician reported assessments of disease activity, safety parameters, clinical response indicators.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00234897
|United States, Illinois|
|Global Medical Information - Abbott|
|North Chicago, Illinois, United States, 60064|
|Study Director:||Beverly Paperiello||Abbott|